# Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

> **NCT01254422** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 250 (actual)

## Conditions studied

- Dengue Fever
- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- **BIOLOGICAL:** Placebo: NaCl 0.9%

## Key facts

- **NCT ID:** NCT01254422
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-02
- **Primary completion:** 2012-09-28
- **Final completion:** 2013-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254422, "Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01254422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*